Bristol-Myers Squibb (NYSE: BMY) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
This table compares Bristol-Myers Squibb and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Bristol-Myers Squibb pays an annual dividend of $1.56 per share and has a dividend yield of 2.5%. CoLucid Pharmaceuticals does not pay a dividend. Bristol-Myers Squibb pays out 61.4% of its earnings in the form of a dividend. CoLucid Pharmaceuticals has increased its dividend for 7 consecutive years.
Insider & Institutional Ownership
69.7% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. 0.2% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Bristol-Myers Squibb and CoLucid Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bristol-Myers Squibb presently has a consensus price target of $63.92, indicating a potential upside of 3.94%. CoLucid Pharmaceuticals has a consensus price target of $47.83, indicating a potential upside of 2.80%. Given Bristol-Myers Squibb’s stronger consensus rating and higher probable upside, equities analysts clearly believe Bristol-Myers Squibb is more favorable than CoLucid Pharmaceuticals.
Valuation and Earnings
This table compares Bristol-Myers Squibb and CoLucid Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bristol-Myers Squibb||$19.43 billion||5.18||$4.46 billion||$2.54||24.21|
Bristol-Myers Squibb has higher revenue and earnings than CoLucid Pharmaceuticals. CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb beats CoLucid Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.